European Union Fifth Framework project to discover new anti-microbials that target translation in bacteria and fungi
RiboTargets, a structure-based drug discovery company that develops novel anti-bacterial and anti-cancer therapeutics, has entered into a European Union (EU) Fifth Framework project to discover new anti-microbials that target translation in bacteria and fungi.
RiboTargets joins ten other partners involved in the 36-month project, which commences in September 2002, and is one of three non-academic organisations to contribute to the research, reflecting its level of excellence in anti-bacterial drug discovery.
The company is specifically involved in the structural characterisation of RNA-thiazole antibiotic complexes, applying its world-class structure determination capabilities that include both high resolution NMR spectroscopy and X-ray crystallography.
Utilising its multidisciplinary approach to assay design, RiboTargets will develop high throughput screening assays based on ribosomal RNA-inhibitor interactions.
RiboTargets will also work in collaboration with the Medical Research Council (MRC) on ribosome crystallisation, complementing synergies from the company's exclusive consultancy with Venki Ramakrishnan of the MRC's Laboratory of Molecular Biology. RiboTargets' CSO, David Knowles, commented, "We are very excited to be part of this project, which complements our existing research programmes and fits with our drug discovery expertise.
The Fifth Framework provides an excellent platform to convert scientific breakthroughs into innovative, competitive and sustainable products and it positions RiboTargets at the centre of European research for novel anti-bacterial therapeutics targeting translation." Dr Knowles continued, "We are currently involved with an existing EU Fifth Framework project to discover novel antiviral therapies for hepatitis C." As part of the community research policy the Fifth Framework programme supports research and technological development, stimulating transnational collaboration in research, networks of excellence and establishing an environment in Europe that is favourable to innovation.
